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DEAR EDITOR, The first UK national COVID-19 lockdown began
on 23 March 2020. Immediately, almost all outpatient health-
care service requests temporarily focused exclusively on urgent
referrals and 2-week-wait urgent cancer referrals, with restric-
tions due to staff sickness, redeployment and changing work
environments. Additionally, patient anxiety regarding attend-
ing appointments and perceived overburdening of healthcare
resources resulted in fewer presentations.1
Technological advancements have arisen from challenging
circumstances. The National Cancer Registration and Analysis
Service (NCRAS), England, has developed a Rapid Cancer
Registration Dataset (RCRD). Due to automated data feeds, lag
time from diagnosis to registration has been reduced from 18
to 4 months; however, data have not been quality assured to
the same standards and completeness.2,3 We identify how the
pandemic has affected skin cancer.
The RCRD2,3 provides estimates of cancer incidence using
data from January 2018 to November 2020. The main
resource is multidisciplinary team meeting datasets, which are
not a reliable source for basal cell carcinomas (BCCs) and
cutaneous squamous cell carcinomas (cSCCs), effectively
excluding them. RCRD tumour resection procedures are iden-
tified as a definitive treatment, for example an excision but
not a diagnostic biopsy.
A separate tool to identify BCC and cSCC pathology reports
received by NCRAS before registration was developed for
quality assurance; it was not developed to report incidence
and so should be interpreted cautiously.4 Pathology reports
duplicate tumours when there are diagnostic biopsies, re-exci-
sions, recurrences and supplementary reports. Furthermore,
these data have not been quality assessed and therefore they
are best interpreted as a representation of workload rather
than incidence. The date of the report used is the date of sam-
ple collection preferentially.
Both methods are crude and not the gold standard of
tumour registration. Therefore they are not representative of
the true incidence but are rather an early, rapid estimate. All
reported proportions represent a comparison of the same
month or period of the previous year.
In May 2020, melanoma diagnoses reduced to 54%,
increasing to 83% by November 2020. During the 8-month
period from April 2020 to November 2020, melanoma diag-
noses reduced to 72%, with 2671 fewer melanomas diag-
nosed. Likewise, a reduction was seen in the diagnosis of all
malignant cancers (excluding nonmelanoma skin cancer,
NMSC) (74%), prostate cancer (64%), breast cancer (73%)
and lung cancer (88%) over the same period (Figure 1a). The
proportion of resection procedures in May 2020 fell to 69%,
with an increase to 87% by November 2020 (Figure 1b).
Cancer Waiting Times first treatments for melanoma similarly
fell to 58% in May 2020 and rose to 91% by December 2020
(Figure 1c). Pathology reports for cSCCs and BCCs in April
2020 fell to 58% and 22%, respectively. By September 2020
counts increased to 95% for cSCCs and 72% for BCCs
(Figure 1d).
Undoubtedly, fewer cancer diagnoses are being made dur-
ing the pandemic and an incomplete rebound is seen. Mela-
noma incidence decreased more than the incidence of all
cancers overall (excluding NMSC); however, it is comparable
with that of other cancers. BCCs are typically downgraded to
routine pathways once diagnosed unless considered high risk,
and therefore BCC pathology report counts drop substantially
more than for cSCC.
Comparatively, as a proportion of activity for the same
month of the previous year, in Australia, a reduction in surgi-
cal procedures to 82% for cSCC and BCC, and 75% for mela-
noma was seen at the pandemic onset, with a more rapid
recovery.5 In Ontario, Canada, cSCC and BCC biopsies reduced
to 82% and melanoma biopsies to 73% at the onset of the
pandemic, with improvements seen in the following
10 weeks.6 In a study of 143 US practices, melanoma diag-
noses fell to 304%, SCCs to 223% and BCCs to 141% in
April 2020, but have since improved.7 Overall, a less substan-
tial reduction in services is seen in countries where COVID-19
counts remained lower.
The main limitation of these data is the lack of standard
quality assurance as a result of attaining more rapid access to
data. NCRAS report that the RCRD melanoma data reported in
Figure 1(a) record 13% false negative (missing) and 9% false
positive (additional) compared with formally registered cases
in 20182,3 Although crude, these data are essential to under-
standing the wider repercussions of the COVID-19 pandemic
beyond those directly infected. Early concerns precipitated the
‘help us, help you’ National Health Service campaign in Octo-
ber 2020,8 which promoted support for public access to
healthcare services during the pandemic.
It is essential to ensure that skin cancer services continue,
with virtual appointments playing an increasingly important
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role. It is of grave concern that the decline in cancer incidence
represents patients who are likely to present later, resulting in
worse morbidity and mortality outcomes. Further research
must be undertaken to understand better the long-term health-
care consequences of the pandemic to ensure we are able to
prepare for further COVID-19 waves and future national emer-
gencies.
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Figure 1 (a) Cancer diagnoses by cancer group and month, Rapid Cancer Registration Dataset (RCRD), England; working-day-adjusted. (b)
Proportion of tumour resection procedures, by cancer group and month, RCRD, England. (c) First treatments by cancer group and month, Cancer
Waiting Times data, England; working-day-adjusted. (d) Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) pathology
reports received at the National Cancer Registration and Analysis Service, CancerStats2 keratinocyte cancer report, England. All data are
comparisons with the same month in the previous year. NMSC, non-melanoma skin cancer.
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